INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 149 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2018. The put-call ratio across all filers is 0.95 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $7,441,000 | -33.9% | 118,188 | +30.2% | 1.28% | -1.2% |
| Q4 2019 | $11,252,000 | +5.1% | 90,804 | -43.7% | 1.29% | +40.5% |
| Q3 2019 | $10,711,000 | -48.8% | 161,406 | -22.3% | 0.92% | -47.0% |
| Q4 2018 | $20,930,000 | -29.3% | 207,657 | -11.3% | 1.74% | +8.8% |
| Q3 2018 | $29,585,000 | -8.8% | 234,135 | -39.4% | 1.60% | -10.5% |
| Q2 2018 | $32,423,000 | +51.2% | 386,397 | +10.9% | 1.78% | +42.5% |
| Q1 2018 | $21,437,000 | – | 348,454 | – | 1.25% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $14,787,000 | 2.73% |
| DeepCurrents Investment Group LLC | 416,800 | $9,620,000 | 0.33% |
| DUALITY ADVISERS, LP | 105,668 | $2,439,000 | 0.21% |
| EULAV Asset Management | 335,000 | $7,732,000 | 0.21% |
| Virtus ETF Advisers LLC | 19,375 | $447,000 | 0.19% |
| Hennion & Walsh Asset Management, Inc. | 135,214 | $3,121,000 | 0.19% |
| PDT Partners, LLC | 110,592 | $2,552,000 | 0.18% |
| KETTLE HILL CAPITAL MANAGEMENT, LLC | 70,256 | $1,622,000 | 0.16% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $3,896,000 | 0.12% |
| WOODWARD DIVERSIFIED CAPITAL, LLC | 8,939 | $206,000 | 0.12% |